A PEAK3-Based Drug Target: Unlocking the Potential for Therapeutic Intervention

Target Name: PEAK3

NCBI ID: G374872

PEAK3

Other Name(s): PEAK3_HUMAN | Protein PEAK3 | C19orf35 | PEAK family member 3 | putative uncharacterized protein C19orf35

A PEAK3-Based Drug Target: Unlocking the Potential for Therapeutic Intervention

Abstract:

PEAK3, a protein expressed in various tissues, including the brain, has been identified as a potential drug target. This protein plays a crucial role in cellular signaling and has been associated with various neurological disorders. In this article, we will discuss the biology of PEAK3, its potential as a drug target, and the ongoing research in this field.

Introduction:

Post-Translational Modification (PTM) of proteins plays a crucial role in regulation of protein stability, localization, and interactions. PEAK3, a member of the protein kinase C (PKC) family, is a non-catalytic, protein that has been identified to be involved in various cellular processes, including cell signaling, cell division, and neurotransmission. PEAK3 has been shown to play a role in the regulation of neural plasticity, synaptic plasticity, and neuronal communication, which are critical for the development and progression of various neurological disorders.

PEAK3 as a Drug Target:

PEAK3 has been identified as a potential drug target due to its unique biology and its involvement in various neurological disorders. PEAK3 has been shown to play a role in the regulation of neurotransmitter release, which is critical for the function of neurons and neurotransmitter systems. PEAK3 has also been associated with the regulation of cell adhesion, which is critical for the maintenance of neural tissues and for the development of various neurological disorders.

In addition to its role in neurotransmission and cell adhesion, PEAK3 has also been shown to play a role in the regulation of inflammation, which is critical for the development of various autoimmune disorders. PEAK3 has been shown to play a role in the regulation of pain perception and neuroinflammation, which are critical for the development and progression of chronic pain disorders.

Current Research:

PEAK3 has been shown to be involved in various cellular processes that are crucial for the development and progression of neurological disorders. Currently, there are several ongoing research studies aimed at understanding the role of PEAK3 in neurological disorders.

One of the ongoing studies is focused on the role of PEAK3 in the development of Alzheimer's disease (AD). This study is designed to determine the role of PEAK3 in the regulation of neurotransmission in AD. The results of this study will provide valuable insights into the potential therapeutic interventions aimed at reducing the risk of AD.

Another study is focused on the role of PEAK3 in the regulation of pain perception and neuroinflammation. This study is designed to determine the role of PEAK3 in the regulation of pain perception and neuroinflammation, with a particular focus on the role of PEAK3 in the development and progression of chronic pain disorders.

Conclusion:

PEAK3 has been identified as a potential drug target due to its unique biology and its involvement in various neurological disorders. Currently, there are several ongoing research studies aimed at understanding the role of PEAK3 in neurological disorders. The results of these studies will provide valuable insights into the potential therapeutic interventions aimed at reducing the risk of neurological disorders.

Protein Name: PEAK Family Member 3

Functions: Probable catalytically inactive kinase (Probable). Interacts with CRK-II and antagonizes CRK-II-signaling. Prevents the formation of CRK-II-dependent membrane ruffling and lamellipodia-like extensions (PubMed:31311869)

The "PEAK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEAK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets